ChemT Biotechnology, an AI-driven biotechnology company based on Singapore, has closed a $4 million seed round led by Wavemaker Ventures and co-investment partner SEEDS, an arm of SG Growth Capital, with support from Wavemaker 360 Health, Draper University Ventures, and Temasek Life Sciences Accelerator.

In a statement on Monday, ChemT Biotechnology said it can build intelligence directly into the biomanufacturing process through CelMo, an AI-driven Virtual Cell platform trained on billions to trillions of proprietary biological sequencing reads and validated in the lab. The platform simulates how cells respond to manufacturing conditions, genetic changes, and stresses, tracking biological processes such as growth, metabolism, and stress response to build a dynamic picture of cell behavior during manufacturing.

Jie Sun, co-founder and CEO of ChemT Biotechnology, said the financing validates the company’s team and technology during a difficult funding environment for life sciences, noting that within roughly a year and a half of launch, ChemT has built commercial partnerships with more than 40 pharmaceutical, biotech, and CDMO companies globally.

The funding will support expansion of ChemT Biotechnology’s AI and experimental infrastructure, advancement of its molecular products toward GMP standards, and further development of CelMo, including expansion beyond CHO and T cells into stem cells, NK cells, and HEK cells.

Paul Santos, Co-founder and Managing Partner of Wavemaker Partners, said biomanufacturing has long been constrained by a lack of computational understanding of cellular networks, and that ChemT’s precision small molecules give manufacturers a new lever for faster, cheaper, and higher-yield production.

Convergence in the blood: How AI and biotech are rewriting cancer detection across Asia